Compare BioNTech SE - ADR (BNTX) vs Invesco S&P 500 Momentum ETF (SPMO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Invesco S&P 500 Momentum ETF — how do they compare? BioNTech SE - ADR trades at $89.89 (market cap $22.86B), while Invesco S&P 500 Momentum ETF trades at $153.2. The key difference: Invesco S&P 500 Momentum ETF is trading nearer its 52-week high, BioNTech SE - ADR nearer its low. Which is the better fit depends on your goals.
| BNTX | SPMO | |
|---|---|---|
Market Cap | $22.86B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $119.34 | $161.66 |
52-Week Low | $83.89 | $107.84 |
Enterprise Value | $6.53B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
SPMO trades at $149.73, down 2.61% today, with a neutral technical signal. The ETF maintains a bullish moving average trend but faces resistance near $150. Recent news highlights strong momentum performance, gaining 7.5% in June 2026, driven by concentrated technology exposure and AI beneficiaries. A dividend of $0.25 is scheduled for June 2026.
Outlook remains positive with AI-driven growth potential, but risks include high volatility from sector concentration. Analyst sentiment is mixed, with some recommending buys for momentum exposure. Key support is at $149, with upside resistance at $151-$153.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Invesco S&P 500 Momentum ETF
SPMO is designed to track the investment results of the S&P 500 Momentum Index. This index measures the performance of stocks in the S&P 500 that exhibit the highest momentum, or the greatest price appreciation, over the trailing 12 months, while excluding the most recent month. By investing in these high-momentum stocks, SPMO seeks to capitalize on the historical trend that stocks with strong recent performance tend to continue that performance in the near term, offering a systematic approach to factor investing within the large-cap U.S. equity market.
Read more on SPMO →
